Understanding the role of MRAs in management of heart failure with Cardiologist Dr Rajeev Agarwala
Designated as an emerging epidemic in 1997, Heart failure is still a major clinical and public health concern. Many medicines previously used have gone into disrepute, while many others have been found to be useful. Recently, 2021 update on the 2017 ACC expert consensus decision pathway has upgraded mineralocorticoid receptor antagonist (MRA) as a class 1 indication for the treatment of...
Designated as an emerging epidemic in 1997, Heart failure is still a major clinical and public health concern. Many medicines previously used have gone into disrepute, while many others have been found to be useful.
Recently, 2021 update on the 2017 ACC expert consensus decision pathway has upgraded mineralocorticoid receptor antagonist (MRA) as a class 1 indication for the treatment of Heart failure with reduced ejection fraction.
Dr Rajeev Agarwala , an eminent cardiologist explains the role of MRAs in the management of heart failure.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd